Biodexa Pharmaceuticals Plc

NasdaqCM:BDRX Stock Report

Market Cap: US$1.8m

Biodexa Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Stephen Stamp

Chief executive officer

UK£364.5k

Total compensation

CEO salary percentage68.59%
CEO tenure6.3yrs
CEO ownershipn/a
Management average tenure3.4yrs
Board average tenure8.6yrs

Recent management updates

Recent updates

Midatech Pharma regains compliance with Nasdaq's minimum bid price requirement

Oct 18

Midatech Pharma reports 1H results

Sep 14

CEO Compensation Analysis

How has Stephen Stamp's remuneration changed compared to Biodexa Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-UK£6m

Mar 31 2025n/an/a

-UK£6m

Dec 31 2024UK£364kUK£250k

-UK£6m

Sep 30 2024n/an/a

-UK£6m

Jun 30 2024n/an/a

-UK£7m

Mar 31 2024n/an/a

-UK£7m

Dec 31 2023UK£252kUK£250k

-UK£7m

Sep 30 2023n/an/a

-UK£8m

Jun 30 2023n/an/a

-UK£8m

Mar 31 2023n/an/a

-UK£8m

Dec 31 2022UK£238kUK£236k

-UK£8m

Sep 30 2022n/an/a

-UK£7m

Jun 30 2022n/an/a

-UK£5m

Mar 31 2022n/an/a

-UK£5m

Dec 31 2021UK£329kUK£187k

-UK£5m

Sep 30 2021n/an/a

-UK£7m

Jun 30 2021n/an/a

-UK£8m

Mar 31 2021n/an/a

-UK£15m

Dec 31 2020UK£193kUK£175k

-UK£22m

Jun 30 2020n/an/a

-UK£22m

Mar 31 2020n/an/a

-UK£16m

Dec 31 2019UK£207kUK£50k

-UK£9m

Compensation vs Market: Stephen's total compensation ($USD492.17K) is about average for companies of similar size in the US market ($USD576.67K).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.

CEO

Stephen Stamp (64 yo)

6.3yrs
Tenure
UK£364,471
Compensation

Mr. Stephen Anthony Stamp serves as Chief Financial Officer and Director of Biodexa Pharmaceuticals Plc (formerly known as Midatech Pharma plc) since September 9, 2019. He serves as Chief Executive Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Stephen Stamp
CEO, CFO6.3yrsUK£364.47kno data
Daniel Palmer
Vice President of Technology4.9yrsno datano data
Steve Ellul
Chief Business Officer1.9yrsno datano data
Gary Shangold
Chief Medical Officerless than a yearno datano data
Fiona Sharp
Group Financial Controllerno datano datano data
Noreen Bhatti
Vice President of Clinical Operationsno datano datano data
3.4yrs
Average Tenure

Experienced Management: BDRX's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Stamp
CEO, CFO6.3yrsUK£364.47kno data
Simon Turton
Senior Independent Non-Executive Director11yrsUK£116.09k0%
$ 0
Stephen Parker
Independent Non-Executive Chairman3.5yrsUK£234.17k0%
$ 0
Daniel McCurdy
Member of Scientific Advisory Boardno datano datano data
Sijmen de Vries
Independent Non-Executive Director21.2yrsUK£116.09k0%
$ 0
Michael Natan
Member of Scientific Advisory Boardno datano datano data
Francesco Stellaci
Chairman of Scientific Advisory Boardno datano datano data
David Male
Member of Scientific Advisory Boardno datano datano data
Lorraine O'Driscoll
Member of Scientific Advisory Boardno datano datano data
Soledad Penades
Member of Scientific Advisory Boardno datano datano data
Jean-Christophe Roux
Member of Scientific Advisory Boardno datano datano data
Silke Krol
Member of Scientific Advisory Boardno datano datano data
8.6yrs
Average Tenure
66yo
Average Age

Experienced Board: BDRX's board of directors are considered experienced (8.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 09:09
End of Day Share Price 2025/12/26 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biodexa Pharmaceuticals Plc is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aydin HuseynovLadenburg Thalmann & Company
Jens LindqvistSinger Capital Markets